Clearside Biomedical, Inc. (CLSD)

NASDAQ: CLSD · IEX Real-Time Price · USD
1.50
0.00 (0.00%)
At close: Aug 18, 2022 4:00 PM
1.47
-0.03 (-2.00%)
After-hours: Aug 18, 2022 7:58 PM EDT
0.00%
Market Cap 90.29M
Revenue (ttm) 29.49M
Net Income (ttm) -1.64M
Shares Out 60.19M
EPS (ttm) 0.01
PE Ratio 150.00
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 137,384
Open 1.49
Previous Close 1.50
Day's Range 1.48 - 1.54
52-Week Range 1.26 - 7.73
Beta 1.91
Analysts Buy
Price Target 7.65 (+410.0%)
Earnings Date Aug 9, 2022

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. T... [Read more...]

Industry Pharmaceuticals
IPO Date Jun 2, 2016
CEO George Lasezkay
Employees 34
Stock Exchange NASDAQ
Ticker Symbol CLSD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 410.00% from the latest price.

Price Target
$7.65
(410.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0% and 48.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 -

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

- Transaction Supports Progression of CLS-AX Clinical Program - - Transaction Supports Progression of CLS-AX Clinical Program -

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the supr...

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August ...

ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the supr...

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

- Multiple Podium and Poster Presentations on XIPERE ® and Gene Therapy Delivery Utilizing SCS Microinjector ® -

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

- Seasoned Life Science Executive Brings Expertise in Ophthalmic Clinical Development, Including Advancement of Multiple Late-Stage Programs to Product Approval - - Seasoned Life Science Executive Bring...

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the sup...

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -333.33% and 96.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st...

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

- First Approved Suprachoroidal Product, XIPERE ® , Now Commercially Available in U.S. -

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Deliv...

- Multiple Poster Presentations on XIPERE ® and Gene Therapy Delivery Utilizing SCS Microinjector ® -

Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11...

ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the sup...

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Inject...

XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga. , March 28, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health bus...

Why Clearside Biomedical Shares Are Surging Today

Clearside Biomedical Inc (NASDAQ: CLSD) shares are trading higher Friday after the company reported better-than-expected fourth-quarter financial results.  Clearside reported quarterly revenue of $25.69...

Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 244.44% and 95.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the ...

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- XIPERE ® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 -

Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D.

Industry Veteran Brings Broad Ophthalmology Research & Development Expertise Industry Veteran Brings Broad Ophthalmology Research & Development Expertise

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...

Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Th...

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the supr...

Clearside Biomedical's Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 20...

- Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Agents to the Retina and Choroid - - Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Agent...

Clearside Biomedical's Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degenerat...

Clearside's suprachoroidal space (SCS®) injection platform to be featured at top medical meeting and also at Raymond James Angiogenesis Preview Event Clearside's suprachoroidal space (SCS®) injection pl...

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injec...

- Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events –- Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to Coho...